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Tardive dyskinesia (TD),literally meaning a late occurring, abnormal movement disorder, was first described by Schonecker in 1957, about five years after the discovery of chlorpromazine (cited in Kane, 1992) . TD generally occurs after long-term antipsychotic therapy: Kane et al (1984) reported that the incidence was in creased with each subsequent year of exposure to antipsychotics, starting with an incidence of 5% after one year of exposure and increasing by 5% each subsequent year. Certainly, the pre valence of TD has increased over the last 20 years, probably as the result of more patients being exposed to antipsychotics for longer periods.
TD is commonly characterised by lip smack ing and chewing, often with episodic tongue protrusion ("fly-catching") or pushing the tongue into the inner cheek or lip. Grimacing and other facial muscle movements can occur forming the buccolingual masticatory syn drome. Other abnormal movements which can appear include choreiform movements of the hands ("piano-playing"), pelvic-thrusting or rocking of the legs. In severe TD, there may be problems with speaking and eating as well as difficulty in breathing and swallowing. The movements seen in TD are involuntary, although patients may be able to suppress their occurrence for short periods. Tardive dystonia, akathisia, Tourette's, myoclonus and other syndromes have also been described.
It has been postulated that TD develops as a result of dopamine receptor blockade, leading to supersensitivity of the postsynaptic dopa mine receptors. Certainly, similarities exist between TD symptomatology and levodopainduced dyskinesias seen in Parkinson's dis ease, and TD symptoms often resolve on increasing the dose of antipsychotic, while decreasing the antipsychotic dose can lead to exacerbations. Also, dopamine agonists may increase TD symptoms. However, this dopa mine supersensitivity can occur within weeks of starting an antipsychotic, whereas TD does not usually become evident for months or years. A hypernoradrenergic state, deficiency in gamma-aminobutyric acid (GABA), as well as involvement of serotonin, free radicals, neuropeptides and numerous other hypotheses have been proposed (see review of Lohr & Jeste, 1992) .
As there have been no proven safe and effective treatments for TD, the most important step is to prevent its development (Table 1) . Once signs of TD are evident, management will often depend on the underlying psychiatric illness. If the patient does not have a psychotic illness, drugs other than antipsychotics should be tried. In those with schizophrenia or other psychoses, treatment becomes more compli cated. The antipsychotic dose should be slowly decreased over a period of several months and, if possible, stopped. As anticholinergics may exacerbate TD, they should also be discontin ued, although this is still controversial (see discussion of Jeste & Caligiuri. 1993) . With discontinuation of medications, 36-55% of patients will have spontaneous improvement in their symptoms, although such improvement is often delayed and may take up to five years (Miyasaki & Lang, 1995) .
Obviously, discontinuation of antipsychotics is not possible in every patient and the risk of relapse or psychosis must be balanced against the risk of TD. In patients where antipsychotics cannot be discontinued, there is evidence that TD is not necessarily progressive in all cases (Lohr & Jeste, 1992) and that continuation at the lowest possible dose minimises the risk of progression (Kane. 1992). One should watch for the occurrence of withdrawal dyskinesias dur ing antipsychotic taper, but be aware that their emergence does not necessarily herald the onset of or exacerbation of TD. TD may, however, be unmasked during antipsychotic withdrawal, but this should not be a deterrent to the clinician to attempt to minimise the dose. Some earlier studies suggested that reducing cumulative neuroleptic exposure may decrease the risk of developing TD, leading to recom mendations for drug holidays. There has since, however, been some evidence that repeated interruption of maintenance antipsychotic treatment may actually increase the risk of developing TD and increase psychiatric morbidity compared with continuous low dose Case reports of short-term efficacy, but also reports of exacerbation From reviews of Lohr & Jeste, 1992; Bazire, 1996; Miyasaki & Lang, 1995. Tardive dyskinesia treatment (see discussion of Jeste & Caligiuri, 1993) . There is thus no indication for drug holidays in the prevention of TD. Because clozapine, olanzapine and sertindole are unlikely to cause extrapyramidal sideeffects, they may not be associated with TD, and so should be considered if an antipsychotic is required. Sulpiride and risperidone may also be somewhat less likely to cause TD than standard antipsychotics.
Clozapine may even be a treatment option for TD. Lieberman et al (1991) , in a review of eight published studies, examined the outcome of 30 patients with TD treated with clozapine for up to 36 monthÂ» and found a 50% or greater reduction in TD symptoms in approximately 43% of cases. Benefits were greatest in patients with severe TD, particularly tardive dystonia. Some im provement was also noted in patients with typical choreoathetoid symptoms. However, definitive conclusions could not be made due to methodological limitations. Shapleske et al (1996) recenÃ¼yreported the successful treatment of tardive dystonia with clozapine and clonazepam in combination. Clo zapine alone had only limited success but within two weeks of adding clonazepam (3 mg/day), there was a virtually complete resolution of all abnormal movements. Moreover, this improve ment was sustained at follow-up, almost two years later.
Increasing the antipsychotic dose has been suggested as a treatment option. While this may ameliorate the symptoms in the short term, it usually exacerbates them in the long term. Reserpine, tetrabenazine and other dopaminedepleting drugs have been used with some success but their side-effects (e.g. worsening of Parkinsonism, depression, sedation) often limit their usefulness. There have been anecdotal reports for efficacy of cholinomimetics, various GABA agonists, dopamine agonists and numer ous other agents. There have however been very few controlled trials of these agents.
Of those agents which have been studied. Vitamin E appears to diminish symptoms of TD in some patients. There have been several double-blind, placebo-controlled trials of Vita min E in doses of 800-1600 I.U./day showing some beneficial effect, particularly in patients who have had TD for five years or less (Lohr et al 1987; Elkashef et al, 1990; Egan et al, 1992 : Dabin et al, 1994 : Lohr & Caligiuri, 1996 , although this is controversial.
Sideeffects include nausea, vomiting, abdominal cramps, diarrhoea, headache, fatigue and allergic reactions. Although it appears to be generally well tolerated at this stage, its efficacy, the necessary treatment duration and specific indications are not yet clearly established. Thaker et al (1990) , in a 12-week, doubleblind, placebo-controlled, randomised crossover trial, tested clonazepam in 19 patients with TD. Eighteen of the 19 patients were being treated with antipsychotics (mean chlorpromazine equivalent dose, 1291 (s.d. 1372) mg/day). Clonazepam in doses of 2-4.5 mg/day reduced dyskinesia scores overall by 37.1%. This effect was reversed with placebo administration. Clonazepam was more effective in patients with dystonic than in those with choreoathetoid symptoms. In the five patients who continued with the clonazepam long-term, after trial completion, tolerance developed to the antidyskinetic effects. Clonazepam was, however, effec tive again in these patients following a two-week drug-free period. This agent may thus be particularly useful for intermittent treatment such as in social situations where suppression of TD symptoms would be highly desirable.
Other drugs that have shown some promise in the treatment of TD include nifedipine. valproate, specific GABA agonists (not widely available) and botulinum toxin (for the treat ment of tardive dystonia only). Although dopa mine agonists as well as y-vinyl GABA (vigabatrin) have been reported to improve TD, they may also cause psychosis as an adverse effect and cannot thus be routinely recom mended in patients with psychosis and TD. Table 2 shows the various classes of drugs used in TD, and Table 3 summarises our treatment recommendations. 
